SCHEMBL1064258

SCHEMBL1064258

N#Cc1ccc(Cn2cncc2C=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 17/20 1.00
CYP11B2 P19099 17/20 1.00
CYP19A1 P11511 3/20 0.62
FNTA P49354 1/20 0.46
FNTB P49356 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7694608 0.86 CYP11B1 (0.75) CYP11B1CYP11B2CYP19A1FNTAFNTB
SCHEMBL8209046 0.85 CYP11B1 (0.74) CYP11B1CYP11B2CYP19A1
SCHEMBL8139285 0.83 CYP11B1 (0.71) CYP11B1CYP11B2CYP19A1
SCHEMBL1758083 0.81 CYP11B1 (0.68) CYP11B1CYP11B2CYP19A1
SCHEMBL7700254 0.80 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1
SCHEMBL8140959 0.80 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1FNTAFNTB
SCHEMBL765399 0.80 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1
SCHEMBL7986619 0.80 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1
SCHEMBL7696780 0.80 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1
SCHEMBL7499526 0.80 CYP11B1 (0.68) CYP11B1CYP11B2CYP19A1FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009106640-A2 N-BENZYL IMIDAZOLE DERIVATIVES MAASTRICHT UNIVERSITY (NL) 2009-09-03 WO claimed
EP-2095819-A1 N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors Maastricht University (NL) 2009-09-02 EP claimed
US-20250114350-A1 INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2025-04-10 US disclosed
US-20130289086-A1 Aminopyrrolidinone Derivatives and Uses Thereof DUGGAN MARK E (US) 2013-10-31 US disclosed
US-20130289086-A1 Aminopyrrolidinone Derivatives and Uses Thereof DUGGAN MARK E (US) 2013-10-31 US disclosed
US-20130289086-A1 Aminopyrrolidinone Derivatives and Uses Thereof DUGGAN MARK E (US) 2013-10-31 US disclosed
US-8252829-B2 Aminopyrrolidinone derivatives and uses thereof LINK MEDICINE CORPORATION (US) 2012-08-28 US disclosed
US-8252829-B2 Aminopyrrolidinone derivatives and uses thereof LINK MEDICINE CORPORATION (US) 2012-08-28 US disclosed
US-8252829-B2 Aminopyrrolidinone derivatives and uses thereof LINK MEDICINE CORPORATION (US) 2012-08-28 US disclosed
EP-2438059-A1 AMINOPYRROLIDINONE DERIVATIVES AND USES THEREOF Link Medicine Corporation (US) 2012-04-11 EP disclosed
US-7943635-B2 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2011-05-17 US disclosed
WO-1997036591-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 WO disclosed
WO-1997036593-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 WO disclosed
WO-1997036587-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-10-09 WO disclosed
WO-1997036583-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 WO disclosed
WO-1997027853-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-08-07 WO disclosed
WO-1997027752-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-08-07 WO disclosed
WO-1996039137-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-12-12 WO disclosed
WO-1996037204-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-11-28 WO disclosed
WO-1996030343-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114350-A1 INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS FNTA, FNTB, FDPS CYP11B1 3101/4885CYP11B2 3669/4885CYP19A1 3254/4885
US-20130289086-A1 Aminopyrrolidinone Derivatives and Uses Thereof PRMT1, PRMT5, AGTR2 CYP11B1 91/4885CYP11B2 57/4885CYP19A1 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.